Please login to the form below

Not currently logged in
Email:
Password:

Alapis opens veterinary companies in Serbia and Hungary

Alapis establishes two companies in Serbia and Hungary which will specialise in the production and trade of veterinary medicines and foods

Greek pharmaceutical and chemical company Alapis has established two companies, one in Serbia and another in Hungary, both of which will specialise in the production and trade of veterinary medicines and foods.

The Serbia-based operation is called Veterin Pharma Doo and has its headquarters in Beograd. The other company, based in Budapest, Hungary, is called Veterin Hungary. Alapis is the sole share holder in both companies.

Other purchasing activity
On 25 July, Alapis said that it had been selected as the highest bidder by the Serbian Privatisation Agency for the sale of a 68.3 per cent stake in pharmaceutical distribution company Sumadijalek after it bid EUR 2.2m.

Sumadijalek was founded in 1965 and had turnover of EUR 9.4m in FY05 with 48 per cent of its sales coming from pharmacies, clinics and public hospitals.

Alapis reported that negotiations would begin with the agency for the purpose of signing the contract of purchase.

In early July, Alapis revealed that it was in preliminary talks with Bayer Cropscience's local unit Bayer Hellas to acquire its pesticide plant in Viotia, Greece. As part of the transaction, Alapis said it expected to take over the production of crop chemicals in the region for Bayer.

Alapis already co-operates with Germany-headquartered Bayer on the production of veterinary drugs in Greece, Romania and Bulgaria.

1st August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics